Under atezolizumab treatment, CRTC1 overexpression in LLC tumors accelerated tumor growth, reduced tumor cell death (Figures 1H–K), and upregulated PD-L1 (Figure 1L). The gene discussed is CRTC1; the disease is neoplasm.